Cat. No.: DAB-0012761
Product Information | |
---|---|
Clonality | Monoclonal |
Isotype | IgG |
Host Species | Rabbit |
Reactivity | Human |
Applications | WB, IHC |
Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Asp518 of human prolactin receptor protein. |
Format | Liquid |
Purity | Affinity purity |
Target Information | |
---|---|
Target Name | PRLR |
UniProt No. | P16471 |
Gene ID | 5618 |
Gene Description | Prolactin receptor is a single-pass transmembrane receptor that mediates the actions of prolactin, a peptide hormone secreted by the anterior pituitary. PRLR is a type 1 cytokine receptor that is best known for promoting lactation in mammals, but which is also implicated in osmoregulation, metabolism, and immune system function. Research studies suggest that PRLR activation may promote tumor growth. Prolactin signaling via PRLR can activate multiple signal transduction pathways in breast cancer cells, including the Jak/Stat, PI3K/Akt, and MAPK pathways, leading to both pro-proliferative and anti-apoptotic downstream effects. Nine isoforms of PRLR have been identified, with the canonical isoform primarily responsible for the pro-oncogenic effects of PRLR in some cancer cell lines. Much less is known about the functions of the other prolactin receptor isoforms. Defining the precise role of PRLR in promoting growth of breast cancer and other tumor types remains an area of active investigation. |
Shipping & Storage | |
---|---|
Shipping | Shipped at 4 °C. |
Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.